A Robustness Analysis of Dynamic Boolean Models of Cellular Circuits

A Strategy Utilizing Protein-Protein Interaction Hubs for the Treatment of Cancer Diseases

We describe a strategy for the development of a rational approach of neoplastic disease therapy based on the demonstration that scale-free networks are susceptible to specific attacks directed against its connective hubs. This strategy involves the (i) selection of up-regulated hubs of connectivity in the tumors interactome, (ii) drug repurposing of these hubs, (iii) RNA silencing of non-druggable hubs, (iv) in vitro hub validation, (v) tumor-on-a-chip, (vi) in vivo validation, and (vii) clinical trial. Hubs are protein targets that are assessed as targets for rational therapy of cancer in the context of personalized oncology. We confirmed the existence of a negative correlation between malignant cell aggressivity and the target number needed for specific drugs or RNA interference (RNAi) to maximize the benefit to the patient's overall survival. Interestingly, we found that some additional proteins not generally targeted by drug treatments might justify the addition of inhibitors designed against them in order to improve therapeutic outcomes. However, many proteins are not druggable, or the available pharmacopeia for these targets is limited, which justifies a therapy based on encapsulated RNAi.

NSCGRN: a network structure control method for gene regulatory network inference

Accurate inference of gene regulatory networks (GRNs) is an essential premise for understanding pathogenesis and curing diseases. Various computational methods have been developed for GRN inference, but the identification of redundant regulation remains a challenge faced by researchers. Although combining global and local topology can identify and reduce redundant regulations, the topologies' specific forms and cooperation modes are unclear and real regulations may be sacrificed. Here, we propose a network structure control method [network-structure-controlling-based GRN inference method (NSCGRN)] that stipulates the global and local topology's specific forms and cooperation mode. The method is carried out in a cooperative mode of 'global topology dominates and local topology refines'. Global topology requires layering and sparseness of the network, and local topology requires consistency of the subgraph association pattern with the network motifs (fan-in, fan-out, cascade and feedforward loop). Specifically, an ordered gene list is obtained by network topology centrality sorting. A Bernaola-Galvan mutation detection algorithm applied to the list gives the hierarchy of GRNs to control the upstream and downstream regulations within the global scope. Finally, four network motifs are integrated into the hierarchy to optimize local complex regulations and form a cooperative mode where global and local topologies play the dominant and refined roles, respectively. NSCGRN is compared with state-of-the-art methods on three different datasets (six networks in total), and it achieves the highest F1 and Matthews correlation coefficient. Experimental results show its unique advantages in GRN inference.

Boolean modelling as a logic-based dynamic approach in systems medicine

Molecular mechanisms of health and disease are often represented as systems biology diagrams, and the coverage of such representation constantly increases. These static diagrams can be transformed into dynamic models, allowing for in silico simulations and predictions. Boolean modelling is an approach based on an abstract representation of the system. It emphasises the qualitative modelling of biological systems in which each biomolecule can take two possible values: zero for absent or inactive, one for present or active. Because of this approximation, Boolean modelling is applicable to large diagrams, allowing to capture their dynamic properties. We review Boolean models of disease mechanisms and compare a range of methods and tools used for analysis processes. We explain the methodology of Boolean analysis focusing on its application in disease modelling. Finally, we discuss its practical application in analysing signal transduction and gene regulatory pathways in health and disease.